Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Down 10.1% – What’s Next?

13 Jan 2026, 17:38 by Scott Moore · The Cerbat Gem

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report)’s share price traded down 10.1% during mid-day trading on Tuesday . The stock traded as low as $10.60 and last traded at $10.19. 2,964,974 shares were traded during trading, an increase of 15% from the average session volume of 2,568,470 shares. The stock had previously closed at $11.33.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on DAWN shares. TD Cowen initiated coverage on shares of Day One Biopharmaceuticals in a research report on Tuesday. They set a “buy” rating and a $34.00 price target on the stock. JPMorgan Chase & Co. upped their target price on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Piper Sandler lifted their price target on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Zacks Research upgraded Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $16.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Day One Biopharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $25.71.

Get Our Latest Stock Report on DAWN

Day One Biopharmaceuticals Trading Down 6.5%

The stock has a market cap of $1.09 billion, a PE ratio of -6.97 and a beta of -1.27. The business has a 50-day moving average price of $9.02 and a 200 day moving average price of $7.71.

Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.09. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. The company had revenue of $39.80 million for the quarter, compared to analyst estimates of $38.20 million. During the same quarter in the previous year, the firm posted $0.38 earnings per share. The company’s quarterly revenue was down 57.6% compared to the same quarter last year. On average, equities analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.

Insider Activity

In other Day One Biopharmaceuticals news, insider Adam Dubow sold 4,319 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $8.91, for a total value of $38,482.29. Following the completion of the transaction, the insider directly owned 62,626 shares of the company’s stock, valued at $557,997.66. This trade represents a 6.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Charles N. York II sold 4,062 shares of the business’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $8.91, for a total transaction of $36,192.42. Following the transaction, the chief financial officer owned 294,715 shares of the company’s stock, valued at $2,625,910.65. This trade represents a 1.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 28,001 shares of company stock valued at $249,489 over the last ninety days. 6.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada increased its stake in Day One Biopharmaceuticals by 40.4% in the 1st quarter. Royal Bank of Canada now owns 185,733 shares of the company’s stock worth $1,474,000 after acquiring an additional 53,459 shares during the last quarter. AQR Capital Management LLC raised its stake in Day One Biopharmaceuticals by 601.4% in the first quarter. AQR Capital Management LLC now owns 618,627 shares of the company’s stock valued at $4,906,000 after purchasing an additional 530,429 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Day One Biopharmaceuticals by 6.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,992 shares of the company’s stock valued at $302,000 after purchasing an additional 2,149 shares during the last quarter. Millennium Management LLC grew its stake in Day One Biopharmaceuticals by 587.2% in the 1st quarter. Millennium Management LLC now owns 1,320,095 shares of the company’s stock worth $10,468,000 after buying an additional 1,127,995 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Day One Biopharmaceuticals by 232.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,569,918 shares of the company’s stock worth $12,449,000 after buying an additional 1,097,679 shares during the last quarter. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

(Get Free Report)

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.